Investors.com – Valeant Pharmaceuticals (NYSE:VRX) shares sharply lower Tuesday as Q3 earnings miss estimates.
Valeant shares were down 8% at $17.50 in pre-market trade.
Valeant Q3 adjusted EPS $1.55 vs estimate $1.75 and $2.41 a year earlier.
Revenues down 11% yoy at $2.48 bn vs estimate of 2.54 bn.
Cuts FY EPS guidance to $5.30-$5.50 from $6.60-$7.00.
Revenue guidance lowered to $9.55-$9.65 bn from $$9.9-$10.1 bn